Effects of Salt Supplementation on the Albuminuric Response to Telmisartan With or Without Hydrochlorothiazide Therapy in Hypertensive Patients With Type 2 Diabetes Are Modulated by Habitual Dietary Salt Intake by Ekinci, Elif I. et al.
Effects of Salt Supplementation on the
Albuminuric Response to Telmisartan With
or Without Hydrochlorothiazide Therapy
in Hypertensive Patients With Type 2
Diabetes Are Modulated by Habitual
Dietary Salt Intake








RICHARD J. MACISAAC, PHD
1










OBJECTIVE — This prospective randomized double-blind placebo-controlled crossover
study examined the effects of sodium chloride (NaCl) supplementation on the antialbuminuric
action of telmisartan with or without hydrochlorothiazide (HCT) in hypertensive patients with
type 2 diabetes, increased albumin excretion rate (AER), and habitual low dietary salt intake
(LDS;100mmolsodium/24hontwoofthreeconsecutiveoccasions)orhighdietarysaltintake
(HDS; 200 mmol sodium/24 h on two of three consecutive occasions).
RESEARCH DESIGN AND METHODS — Following a washout period, subjects (n 
32)received40mg/daytelmisartanfor4weeksfollowedby40mgtelmisartanplus12.5mg/day
HCT for 4 weeks. For the last 2 weeks of each treatment period, patients received either 100
mmol/day NaCl or placebo capsules. After a second washout, the regimen was repeated with
supplementsinreverseorder.AERandambulatorybloodpressureweremeasuredatweeks0,4,
8, 14, 18, and 22.
RESULTS — In LDS, NaCl supplementation reduced the anti-albuminuric effect of telmisar-
tan with or without HCT from 42.3% (placebo) to 9.5% (P  0.004). By contrast, in HDS, NaCl
supplementation did not reduce the AER response to telmisartan with or without HCT (placebo
30.9%, NaCl 28.1%, P  0.7). Changes in AER were independent of changes in blood pressure.
CONCLUSIONS — The AER response to telmisartan with or without HCT under habitual
low salt intake can be blunted by NaCl supplementation. By contrast, when there is already a
suppressed renin angiotensin aldosterone system under habitual high dietary salt intake, the
additional NaCl does not alter the AER response.
Diabetes Care 32:1398–1403, 2009
R
educing albumin excretion rate
(AER) by blockade of the renin an-
giotensin aldosterone system
(RAAS) and adherence to a low-salt diet
are well recognized strategies for renal
protection in people with diabetes (1,2).
The antiproteinuric effect of RAAS block-
ade is magniﬁed by dietary salt restriction
in nondiabetic subjects with renal disease
(3,4). Furthermore, a low-salt diet poten-
tiates the anti-albuminuric effects of
RAAS inhibition in type 2 diabetic pa-
tients with microalbuminuria (5).
In hypertensive patients without dia-
betes, the antiproteinuric effect of ACE
inhibitors is diminished by high salt in-
take but enhanced by low salt intake or
concurrent administration of a diuretic
(6,7).However,itisnotclearwhetherthe
combination of a diuretic and the angio-
tensin receptor blocker (ARB) telmisartan
hasadditiveeffectsonthealbuminuricre-
sponse in diabetes and whether this re-
sponse is inﬂuenced by habitual dietary
salt intake and additional NaCl. The
present study was therefore designed to
determine if NaCl supplementation re-
duces the anti-albuminuric effects of the
ARB telmisartan with or without the ad-
dition of the thiazide diuretic hydrochlo-
rothiazide(HCT)inhypertensivepatients
with type 2 diabetes, elevated AER, and
either high or low habitual dietary salt
intake.
RESEARCH DESIGN AND
METHODS— We studied 32 patients
with type 2 diabetes, hypertension, and
AER in the range of 10–200 g/min. Par-
ticipants were recruited from the diabetes
clinics at Austin Health, where at each
visit, patients routinely perform a 24-h
urine collection for the measurement of
AER and sodium excretion. Inclusion cri-
teria were type 2 diabetes, hypertension
(blood pressure 140/90 mmHg or tak-
ing antihypertensive therapy), and AER
between 10 and 200 g/min (median of
three consecutive measurements col-
lected over a 12-month period). Patients
were classiﬁed as having a habitually high
dietary salt intake (HDS) on the basis of a
urinarysodiumexcretion200mmol/24
h on two out of three consecutive occa-
sions or habitual low dietary sodium in-
take(LDS)withurinarysodiumexcretion
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are related (8), patients in the HDS and
LDS groups were matched for BMI. Ex-
clusion criteria included serum potas-
sium 5.0 mmol/l, serum creatinine
200 mol/l, AER 200 g/min, A1C
10.0%, and major systemic illness. The
study was approved by the human re-
search ethics committee at Austin Health,
and all participants gave informed con-
sent before commencement of the study.
This trial was registered with the Austra-
lian Clinical Trials Registry (ACTRN
012606000128594).
Study protocol
The study was performed in six phases.
Phase 1, washout (6 to 0 weeks).
There was no change in drug therapy if
sitting blood pressure was 160/95
mmHg. Drugs known to affect the RAAS
were replaced with combinations of vera-
pamil, prazosin, methyldopa, or hydral-
azine at week 6. Titration to achieve
blood pressure 160/95 mmHg was per-
formed between weeks 6 and 3, and
this regimen was continued until the
completion of the trial.
Phase 2, telmisartan, and phase 3,
telmisartan plus HCT (0–8 weeks).
All patients commenced 40 mg daily
telmisartan for 4 weeks followed by 40
mg telmisartan plus 12.5 mg HCT daily
for 4 weeks. HDS and LDS groups re-
ceived NaCl or placebo capsules, in addi-
tiontotheirusualdietandanyofthenon-
RAAS antihypertensive agents started in
phase 2, during the last 2 weeks of telm-
isartan monotherapy and during last 2
weeks of combined telmisartan and HCT
therapy.
Phase 4, second washout (8–14 weeks).
As in phase 1, patients remained on the
background non-RAAS blocking antihy-
pertensive agents.
Phases 5 and 6 (14–22 weeks). Phases
2 and 3 were repeated with placebo and
NaCl capsules in reverse order.
A total of 100 mmol/day of NaCl sup-
plements were administered daily in ﬁve
capsules. Identical placebo capsules con-
tained lactose. Patients were instructed to
take two capsules with breakfast, one
with lunch, and two with their evening
meal. The 24-h urinary AER and sodium
excretion,fastingplasmaglucose,electro-
lytes, A1C, and 24-h ambulatory blood
pressure were measured at 0, 4, 8, 14, 18,
and 22 weeks. In each patient, urinary
sodium excretion was corrected for com-
pletenessofcollectionbyadjustingforav-
erage creatinine excretion in six urine
samples.
All blood samples were taken be-
tween 0800 h and 1000 h in the morning
after an overnight fast and before the ad-
ministration of study medication. Albu-
min concentration was measured by a
turbidimetric SYNCHRON System. The
interassay coefﬁcient of variation was
3.4% for a sample concentration of 112
mg/l. Ambulatory blood pressure was
measured with a portable recording ma-
chine (Spacelabs 90207; Spacelabs Medi-
cal Products, Deerﬁeld, WI) based on an
oscillometric method.
Statistical analysis
AERs are shown as medians with 95% CI.
A logarithmic transformation was applied
to the AER data at baseline and at treat-
ment. The difference, log (AER) during
treatment minus log (AER) at baseline,
was modeled with a three-way ANOVA
using one between-group factor (habitual
dietary sodium intake) and two within-
subject factors (NaCl versus placebo and
telmisartan with or without HCT).
ANOVA was performed using GenStat
10th Edition for Windows. The means
from the three-way ANOVA model were
back-transformed to give an estimate of
the median ratio of treatment/baseline
{thedifferenceoftwologarithms[log(a)–
log(b)] is equal to the logarithm of the
ratio [log(a/b)]; hence a backtransforma-
tiongivestheratioa/b};fromthis,theme-
dian percentage reduction in AER from
baseline was estimated. For example, if
themeanoflogAERtreatmentlogAER
baseline in LDS group receiving telmi-
sartan  placebo was 0.365, a back
transformation of 0.365 produces the
number 0.694 (i.e., e
0.365  0.694).
Hence, the median AER treatment to
baseline ratio was calculated to be 0.694,
and the corresponding percentage reduc-
tion from baseline is 30.6%.
Urinary sodium excretion was also
analyzed using the three-way ANOVA
model. Independent-sample t tests were
used to assess the difference in baseline
characteristics in HDS and LDS groups.
RESULTS
Participants
Of the 32 participants, 17 were recruited
to the HDS group and 15 to the LDS
groupover9months.Threesubjectswere
withdrawn from the HDS group. One re-
quiredsurgeryforbowelobstruction,one
was unable to complete the requirements
of the study, and one was unable to toler-
ate NaCl capsules because of nausea. Al-
though other patients complained of
nausea and vomiting, this was not suf-
ﬁcient to interfere with the study
protocol.
Baseline characteristics of study par-
ticipants are outlined in Table 1. There
were no signiﬁcant differences in age,
BMI,A1C,AER,meanarterialbloodpres-
sure (MAP), smoking status, or use of ad-
ditional antihypertensive agents to
achieve the target blood pressure. There
was also no signiﬁcant difference in AER
assessed at the start of phase 2 and phase








Age (years) 65  2.5 60  1.9 0.16
Male:female ratio 13:1 7:8 0.006
BMI 32.0  0.8 32.9  2.0 0.7
A1C (%) 7.4  0.3 7.4  0.3 0.97
Smoker:nonsmoker 1:13 4:11 0.06
24-h urinary Na excretion (mmol/24 h) 271  24 118  12 0.0001
Ambulatory mean arterial blood pressure (mmHg) 101  2.2 98  2.2 0.24
Mean serum creatinine (mol/l) 92.5  5.4 83.9  5.4 0.24
Estimated glomerular ﬁltration rate (ml/min per
1.73 m
2)
78.1  5.5 78.3  4.2 0.36
Baseline AER* (g/min) geometric mean x/
tolerance factor
34 x/ 1.3 56 x/ 1.4 0.3
Number of patients requiring additional
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men in the HDS group.
Urinary sodium excretion
Attained urinary sodium excretion values
are outlined in Table 2. Throughout the
study, the mean difference in urinary so-
dium excretion between HDS and LDS
groups was 136 mmol/24 h (P  0.001,
95%CI99–174mmol/24h).Themeandif-
ference in urinary sodium excretion be-
tween NaCl supplemented and placebo
groupswas56mmol/24h(P0.001,95%
CI 34–78 mmol/24 h). Treatment with
telmisartan plus HCT was not associated
with an increase in urinary sodium excre-
tion in excess of that seen during treatment
with telmisartan alone (P  0.8).
Blood pressure response
NaCl supplementation was associated
with a statistically signiﬁcant blunting of
antihypertensive effects of telmisartan
and telmisartan plus HCT in both HDS
and LDS groups (Table 2). The change in
MAP during each study period was in-
cluded in the three-way ANOVA statisti-
cal model as a covariate. However, the
change in MAP was not associated with a
signiﬁcant effect on AER (P  0.2).
Albuminuria response
There was no signiﬁcant difference in
baseline AER between the HDS and LDS
groups. Attained AER values through-
out the study are outlined in Table 2.
The major ﬁndings in this study were
thatinthepresenceofNaClsupplemen-
tation, the AER response to telmisar-
tan with or without HCT was reduced
by 	75% in the LDS group and that the
addition of HCT to telmisartan led to an
	45% increase in AER response in both
the HDS and the LDS groups (NaCl vs.
placebo, P  0.004; habitual diet group
[HDS vs. LDS] by supplementation
[NaCl vs. placebo], P  0.02; telmisar-
tan  HCT vs. telmisartan alone, P 
0.01; Table 3, Fig. 1).
NaCl supplementation in HDS and
LDS groups
There was no signiﬁcant difference in the
mean AER response (log treatment  log
baseline) to telmisartan with or without






(mmol/24 h) AER (g/min) MAP (mmHg)
Urinary Na
(mmol/24 h)
Telmisartan  placebo 28.3 (16–55) 96 (89–102) 263 (212–315) 42.3 (24–96) 89 (85–94) 121 (106–137)
Telmisartan  NaCl 25.8 (15–78) 98 (94–103) 314 (260–367) 68.6 (26–124) 93 (89–97) 179 (144–214)
Telmisartan  HCT 
placebo
16.1 (11–44) 91 (85–97) 249 (217–281) 36.9 (15–67) 88 (85–91) 126 (98–154)
Telmisartan  HCT 
NaCl
19.3 (11–67) 96 (91–102) 323 (267–378) 54.1 (22–117) 91 (88–94) 173 (140–207)
Data are means (95% CI). AER, blood pressure, and urinary sodium excretion were measured after 4 weeks of treatment with 40 mg telmisartan daily  12.5 mg
HCT daily. Supplementation with 100 mmol/day salt (NaCl) or placebo was given for the last 2 weeks of treatment with telmisartan with or without HCT.
Table 3—Analysis of treatment effects on AER response according to habitual sodium intake, NaCl versus placebo supplementation, and
telmisartan versus telmisartan plus HCT









HDS Mean (log 
AER treatment–log 
AER baseline) 0.233 0.221 0.507 0.431
HDS median AER (treatment/baseline) ratio 0.792 0.802 0.602 0.650
HDS corresponding percentage decrease 20.8% 19.8% 39.8% 35.0%
LDS mean (log 
AER treatment – log 
AER baseline) 0.365 0.075 0.726 0.126
LDS median AER (treatment/baseline) ratio 0.694 0.928 0.484 0.882
LDS corresponding percentage decrease 30.6% 7.2% 51.6% 11.8%
Effect of habitual diet group on AER response to
short-term NaCl supplementation
Placebo NaCl Difference (placebo – NaCl,
95% CI)
HDS mean (log 
AER treatment – log 
AER baseline) 0.37 0.33 0.04 (0.28 to 0.19)
HDS median AER (treatment/baseline) 0.691 0.719
HDS corresponding percentage decrease 30.9% 28.1%
LDD mean (log 
AER treatment – log 
AER baseline) 0.55 0.10 0.45 (0.68 to 0.21)
LDS median AER (treatment/baseline) 0.577 0.905
LDS corresponding percentage decrease 42.3% 9.5%




Difference (HCT – no HCT,
95% CI)
Mean (log 
AER treatment – log 
AER baseline) 0.22 0.45 0.22 (0.40 to 0.04)
Median AER (treatment/baseline) 0.800 0.640
Corresponding percentage decrease 20.0% 36.0%
Telmisartan  HCT vs. telmisartan alone, P  0.01; NaCl vs. placebo supplementation, P  0.004; habitual diet group (HDS vs. LDS) by supplementation (NaCl
vs. placebo), P  0.02. Telmisartan, 40 mg/day telmisartan; NaCl, salt supplementation 100 mmol NaCl/day; HCT, 12.5 mg/day hydrochlorothiazide.
Salt and microalbuminuria in type 2 diabetes
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the absence of NaCl supplementation.
However, a signiﬁcant decrease in the
AER response was seen with administra-
tion of NaCl compared with placebo cap-
sules (P  0.004). This was mainly
accounted for by a statistically signiﬁcant
two-way interaction of NaCl supplemen-
tation and habitual diet group (P  0.02,
Table 3, Fig. 1).
In the LDS group, the AER response
to telmisartan with or without HCT, ex-
pressed as the percentage decrease from
baseline, was reduced from 42.3% with
placebo to 9.5% with NaCl supplementa-
tion, representing a relative reduction of
77.5%oftheeffectsoftelmisartanHCT
(P  0.02, Fig. 1B). In contrast, in the
HDS group, the percentage reduction in
AERfrombaselinewassimilarduringpla-
ceboandNaClsupplementation(30.9vs.
28.1%, respectively), representing a non-
signiﬁcant relative reduction of 9.1% of
the effects of telmisartan with or without
HCT (P  0.7, Fig. 1B).
Telmisartan versus telmisartan plus
HCT
Dual therapy with telmisartan and HCT
demonstrated an increase in the AER re-
sponse when compared with telmisartan
alone. The percentage reduction in AER
from baseline in subjects treated with
telmisartanalonewas20.0vs.36.0%with
telmisartan plus HCT, representing a rel-
ative reduction of 44% (P  0.01, Table
3). The percentage reduction in AER in
the LDS group treated with telmisartan
without HCT was of similar magnitude to
the reduction in AER in HDS plus telmis-
artan plus HCT (P  0.39).
CONCLUSIONS— The main ﬁnd-
ing of the current study was that, in pa-
tients with habitual low dietary salt
intake, NaCl supplementation resulted in
an 	75% reduction in the AER response
to telmisartan with or without HCT,
whereas NaCl supplementation did not
affect the AER response in the habitual
high dietary salt intake group. Moreover,
the combination of telmisartan and HCT
increased the AER response by 	45%
compared with telmisartan alone in both
the HDS and LDS groups. The changes in
AER seen in this study were independent
of changes in blood pressure.
Theresultsofthisstudyareconsistent
with previous ﬁndings that have found a
relationship between dietary salt intake
and AER, independent of changes in
blood pressure. In a cross-sectional study
from France of 839 normotensive sub-
jects without diabetes, the relationship
between urinary sodium excretion and
AER was independent of sex, age, BMI,
and systolic blood pressure (9). Another
large cross-sectional community study of
7,850 subjects from the Netherlands
showed a positive relationship between
dietary sodium intake and AER that was
independent of other cardiovascular risk
factors including blood pressure (8).
Changes in dietary sodium intake may
have intra-renal effects independent of
blood pressure. A recent study demon-
Figure1—Effectsofsalt(NaCl)supplementationontheAERresponsetotelmisartan(T)  hydrochlorothiazide(HCT)inthehabitualhighdietary
salt (HDS) and low dietary salt (LDS) groups. A: Effects of various treatments on AER. B: Combined analysis of telmisartan  HCT data. A
three-way ANOVA model was used to analyze results by examining the intragroup (NaCl vs. placebo and telmisartan vs. telmisartan plus
hydrochlorothiazide) and the intergroup (HDS vs. LDS) variables. Telmisartan plus HCT vs. telmisartan alone, P  0.01; NaCl vs. placebo
supplementation, P  0.004; habitual diet group (HDS vs. LDS) by supplementation (NaCl vs. placebo), P  0.02.
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notypes may jointly inﬂuence urine
albuminlevelsinuncomplicatedessential
hypertensivemenindependentlyofblood
pressure and other coexisting factors
(10). -Adducin gene exerts complex bi-
ological effects on sodium and volume
homeostasis by interacting with the
epithelial sodium channel, the sodium-
potassium-chloride transporter, and
sodium-potassium adenosine triphospha-
tase (10). Moreover, dietary sodium intake
mayplayanevenmoreimportantroleinthe
pathogenesis of increased albuminuria in
subjectswithdiabetescomparedwiththose
without diabetes because there is an in-
crease in exchangeable sodium in the set-
ting of diabetes (11,12).
To our knowledge, comparisons of
the AER and blood pressure responses to
RAAS blockade and thiazide diuretic in
the setting of habitual high versus low so-
dium intake and the addition of NaCl
have not been performed in humans with
or without diabetes. Only a limited num-
ber of clinical studies have examined the
relationship between dietary sodium in-
take, AER, RAAS blockade, and diuretics.
Studies in subjects with (5) and without
(3,6) diabetes have shown that the anti-
proteinuric effects of RAAS blockade are
dependent on dietary sodium intake. A
low-salt diet increases renal blood ﬂow in
both experimental diabetes (13) and in
type 1 diabetes (14). Furthermore, sub-
jects with type 2 diabetes and hyperten-
sion have reduced renal plasma ﬂow
when dietary salt intake is high (15). The
effectofdietarysaltonthediabetickidney
presents a paradox that cannot be ex-
plained by primary vascular effects of the
neurohormonal or pressure natriuresis
systems (16).
We observed an 	75% reduction in
the AER response to telmisartan with or
withoutHCTintheLDSgroupwithNaCl
supplementation, whereas there was no
differenceintheAERresponseintheHDS
group with the same NaCl supplementa-
tion. Given that the sodium-RAAS rela-
tionship is logarithmic and that the RAAS
ismostlikelytotallysuppressedintheset-
ting of HDS, the addition of NaCl to HDS
does not equate to NaCl addition to the
LDS group. In the HDS group, the mean
baseline urinary sodium excretion was
	270 mmol/24 h, whereas in LDS, it was
	120 mmol/24 h, implying that the
RAAS is fully suppressed during habitual
high salt intake. When related to habitual
salt intake, NaCl supplementation result-
ing in an increase in urinary sodium ex-
cretion of 	60% mmol represents an
increment in urinary sodium excretion of
	50% in the LDS group compared with
anincrementof	25%intheHDSgroup.
Hence, the AER response to telmisartan
with or without HCT under long-term
low-salt intake can still be blunted by
NaCl supplementation, whereas the AER
responseunderlong-termhighsaltintake
is not altered by additional NaCl.
The addition of HCT to telmisartan
increased the AER response by 	45% in
this study. In a previous study in nondia-
betic subjects with overt proteinuria, the
addition of HCT to RAAS blockade led to
afurther56%reductioninproteinuria(7).
However, hydrochlorothiazide mono-
therapy does not appear to inﬂuence pro-
teinuria in nondiabetic (17) and diabetic
subjects (18,19). In our study, the combi-
nation of a thiazide diuretic with RAAS
blockade led to a reduction in AER in the
setting of both high and low sodium in-
take. In the present study, telmisartan
alone in the habitual low dietary salt
group produced a similar AER response
comparedwiththehighdietarysaltgroup
treated with telmisartan plus HCT. This
raises the possibility that potentiating the
anti-albuminuric effects of RAAS inhibi-
tion can possibly be achieved by main-
taining a low habitual salt intake in a
similar fashion to adding a thiazide di-
uretic to subjects with habitual high salt
intake. If patients can maintain a habitual
lowsaltintake,thismightnegatetheneed
for the addition of a thiazide diuretic to
RAAS blockade and hence avoid some of
the potential metabolic effects of thiazide
therapy. However, in clinical practice,
many patients will require the addition of
at least one other antihypertensive agent
to RAAS blockade to achieve blood pres-
suretargetsandreduceAER.Theseagents
are likely to include a thiazide diuretic
and or a calcium channel blocker.
In conclusion, the AER response to
telmisartan with or without HCT during
habitual low salt intake can still be
blunted by NaCl supplementation,
whereas the AER response during habit-
ual high salt intake is not altered by addi-
tional NaCl. In industrialized countries,
dietary sodium consumption is generally
above the recommended targets of 100
mmol/24 h (20,21). Albuminuria has
been considered a risk marker for pro-
gressive loss of renal function in type 2
diabetes with nephropathy, as well as a
target for therapy (22). Based on the re-
sults of the RENAAL study, it has been
suggested that reduction of residual albu-
minuria to the lowest achievable level
shouldbeviewedasagoalforfuturereno-
protective treatments (22). New public
health policies, such as the World Action
on Salt and Health program (23), may fa-
cilitate long-term maintenance of a low
dietary salt intake, and this may help to
maximize the anti-albuminuric effects of
angiotensin receptor blockade with or
without thiazide diuretic therapy. How-
ever, it is not yet known whether changes
in AER associated with variations in di-
etary salt intake will be reﬂected in hard
renal or cardiovascular end points. In ad-
dition, it remains to be shown whether
variations in dietary intake of potassium,
calcium, and magnesium may inﬂuence
theresponseofalbuminuriaand/orblood
pressure to variations in dietary salt
intake.
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